These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 9242437

  • 1. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
    Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG.
    Cancer Res; 1997 Aug 01; 57(15):3126-30. PubMed ID: 9242437
    [Abstract] [Full Text] [Related]

  • 2. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA.
    Cancer Res; 1995 Oct 15; 55(20):4531-5. PubMed ID: 7553622
    [Abstract] [Full Text] [Related]

  • 3. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA.
    Cancer Res; 1996 Mar 01; 56(5):1137-41. PubMed ID: 8640773
    [Abstract] [Full Text] [Related]

  • 4. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN.
    Cancer Res; 1996 Jan 01; 56(1):150-3. PubMed ID: 8548755
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
    Geradts J, Kratzke RA, Niehans GA, Lincoln CE.
    Cancer Res; 1995 Dec 15; 55(24):6006-11. PubMed ID: 8521382
    [Abstract] [Full Text] [Related]

  • 6. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M, Steingrimsdottir H, Elamin F, Gäken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M.
    Br J Cancer; 1999 Apr 15; 80(1-2):79-86. PubMed ID: 10389982
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
    Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB.
    Cancer Res; 1995 Oct 15; 55(20):4525-30. PubMed ID: 7553621
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
    Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ.
    Cancer Res; 1995 Dec 15; 55(24):6200-9. PubMed ID: 8521414
    [Abstract] [Full Text] [Related]

  • 12. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
    Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJ, Lynch HT, Ruggeri BA.
    Mol Carcinog; 1996 Feb 15; 15(2):85-95. PubMed ID: 8599583
    [Abstract] [Full Text] [Related]

  • 13. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
    Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B.
    Cancer Res; 2001 Aug 01; 61(15):5905-10. PubMed ID: 11479232
    [Abstract] [Full Text] [Related]

  • 14. Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas.
    Park HW, Song SY, Lee TJ, Jeong D, Lee TY.
    Oncol Rep; 2007 Jul 01; 18(1):267-72. PubMed ID: 17549378
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A.
    Gynecol Oncol; 2001 Dec 01; 83(3):491-500. PubMed ID: 11733961
    [Abstract] [Full Text] [Related]

  • 17. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.
    Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu AL.
    Clin Cancer Res; 2000 Apr 01; 6(4):1219-28. PubMed ID: 10778944
    [Abstract] [Full Text] [Related]

  • 18. Abrogation of the p16-Rb pathway in Korean hepatocellular carcinomas.
    Lee TJ, Bae JJ, Lee JS, Lee SY, Kim HJ, Kim SK, Lee JY, Lee TY.
    Hepatogastroenterology; 2000 Apr 01; 47(36):1663-8. PubMed ID: 11149028
    [Abstract] [Full Text] [Related]

  • 19. Frequent loss of the P16INK4a gene product in human pituitary tumors.
    Woloschak M, Yu A, Xiao J, Post KD.
    Cancer Res; 1996 Jun 01; 56(11):2493-6. PubMed ID: 8653683
    [Abstract] [Full Text] [Related]

  • 20. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
    Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA.
    Cancer Res; 1999 Jun 15; 59(12):2957-64. PubMed ID: 10383161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.